Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis

Breast Cancer Research and Treatment

Volumn 127, Issue 1, 2011, Pages 1-14

  Wang, Shi Yi ^a   Shamliyan, Tatyana ^a,b   Virnig, Beth A ^a   Kane, Robert ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Minnesota Evidence based Practice Center   (United States)

Author keywords

Ductal carcinoma in situ; Meta analysis; Outcome research; Predictors; Tumor characteristics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TAMOXIFEN;

BREAST DISCHARGE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; META ANALYSIS; OBSERVATIONAL STUDY; PALPATION; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79851509160     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1387-4     Document Type: Review

References (70)

1. GH Sakorafas DR Farley 2003 Optimal management of ductal carcinoma in situ of the breast Surg Oncol 12 221 240 14998563 10.1016/S0960-7404(03)00031-8 (Pubitemid 38281110)
2. SC Lester JL Connolly MB Amin 2009 College of American pathologists protocol for the reporting of ductal carcinoma in situ Arch Pathol Lab Med 133 13 14 19123725
3. J Boyages G Delaney R Taylor 1999 Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis Cancer 85 616 628 10091735 10.1002/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.0.CO;2-7 1:STN:280:DyaK1M7ptVWmtA%3D%3D (Pubitemid 29075283)
4. BA Virnig TM Tuttle T Shamliyan RL Kane 2010 Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes J Natl Cancer Inst 102 170 178 20071685 10.1093/jnci/djp482
5. CJ Allegra DR Aberle P Ganschow, et al. 2010 National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22-24, 2009 J Natl Cancer Inst 102 161 169 20071686 10.1093/jnci/djp485
6. BA Virnig SY Wang T Shamliyan RL Kane TM Tuttle 2010 Ductal carcinoma in situ: risk factors and impact of screening J Natl Cancer Inst Monogr 41 113 116 10.1093/jncimonographs/lgq024
7. RL Kane BA Virnig T Shamliyan SY Wang TM Tuttle T Wilt 2010 The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ J Natl Cancer Inst Monogr 41 130 133 10.1093/jncimonographs/ lgq022
8. T Shamliyan SY Wang BA Virnig TM Tuttle RL Kane 2010 Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ J Natl Cancer Inst Monogr 41 121 129 10.1093/jncimonographs/ lgq034
9. BA Virnig T Shamliyan TM Tuttle RL Kane TJ Wilt 2009 Diagnosis and management of ductal carcinoma in situ Evid Rep Technol Assess 185 1 549
10. DK Owens KN Lohr D Atkins, et al. 2010 AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program J Clin Epidemiol 63 513 523 19595577 10.1016/j.jclinepi.2009.03.009
11. RP Harris M Helfand SH Woolf, et al. 2001 Current methods of the US Preventive Services Task Force: a review of the process Am J Prev Med 20 3 Suppl 21 35 11306229 10.1016/S0749-3797(01)00261-6 1:STN:280:DC%2BD38%2FgvVWquw%3D%3D (Pubitemid 33732964)
12. AJ de Craen J Gussekloo B Vrijsen RG Westendorp 2005 Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia Am J Epidemiol 161 114 120 15632261 10.1093/aje/kwi029 (Pubitemid 40096787)
13. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis, 1st edn. Wiley, New York
14. J Lau JP Ioannidis CH Schmid 1997 Quantitative synthesis in systematic reviews Ann Intern Med 127 820 826 9382404 1:STN:280:DyaK1c%2FgtVOmuw%3D%3D (Pubitemid 27465551)
15. N Bijker P Meijnen JL Peterse, et al. 2006 Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group J Clin Oncol 24 3381 3387 16801628 10.1200/JCO.2006.06.1366 (Pubitemid 46638893)
16. N Bijker JL Peterse L Duchateau, et al. 2001 Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853 J Clin Oncol 19 2263 2271 11304780 1:STN:280:DC%2BD3M3mtFOhtQ%3D%3D (Pubitemid 32366979)
17. B Fisher S Land E Mamounas J Dignam ER Fisher N Wolmark 2001 Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience Semin Oncol 28 400 418 11498833 10.1016/S0093-7754(01)90133-2 1:STN:280: DC%2BD3Mvlt1yjtQ%3D%3D (Pubitemid 32762083)
18. ER Fisher SR Land RS Saad, et al. 2007 Pathologic variables predictive of breast events in patients with ductal carcinoma in situ Am J Clin Pathol 128 86 91 17580274 10.1309/WH9LA543NR76Y29J (Pubitemid 47121719)
19. ER Fisher J Dignam E Tan-Chiu, et al. 1999 Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma Cancer 86 429 438 10430251 10.1002/(SICI)1097- 0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y 1:STN:280: DyaK1Mzlslehsg%3D%3D (Pubitemid 29347405)
20. A Ringberg H Nordgren S Thorstensson, et al. 2007 Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast-results from the Swedish randomised trial Eur J Cancer 43 291 298 17118648 10.1016/j.ejca.2006.09.018 1:STN:280:DC%2BD2s%2FkvVOltg%3D%3D (Pubitemid 46123991)
21. L Holmberg H Garmo B Granstrand, et al. 2008 Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast J Clin Oncol 26 1247 1252 18250350 10.1200/JCO.2007.12.7969
22. SE Pinder C Duggan IO Ellis, et al. 2010 A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial Br J Cancer 103 1 94 100 20517310 10.1038/sj.bjc.6605718 1:STN:280:DC%2BC3cnjsVOitQ%3D%3D
23. Wai ES, Lesperance ML, Alexander CS et al (2010) Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. Ann Surg Oncol 2010. [Epub ahead of print]
24. GL Ottesen HP Graversen M Blichert-Toft IJ Christensen JA Andersen 2000 Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study Breast Cancer Res Treat 62 197 210 11072784 10.1023/A:1006453915590 1:STN:280:DC%2BD3M3osFSntQ%3D%3D
25. MA Ben-David DE Sturtz KA Griffith, et al. 2007 Long-term results of conservative surgery and radiotherapy for ductal carcinoma in situ using lung density correction: the University of Michigan experience Breast J 13 392 400 17593044 10.1111/j.1524-4741.2007.00447.x (Pubitemid 46985566)
26. B Cutuli C Cohen-Solal-Le Nir B De Lafontan, et al. 2001 Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients Eur J Cancer 37 2365 2372 11720829 10.1016/S0959-8049(01)00303-3 1:STN:280:DC%2BD3MnnsV2msg%3D%3D (Pubitemid 33097472)
27. CE Cox M Hyacinthe RJ Gonzalez, et al. 1997 Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: clinical outcome Ann Surg Oncol 4 644 649 9416412 10.1007/BF02303749 1:STN:280: DyaK1c%2FnvVelug%3D%3D (Pubitemid 127725493)
28. Rudloff U, Jacks LM, Goldberg JI et al (2010) Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol (in press)
29. EW Chuwa VH Tan PH Tan WS Yong GH Ho CY Wong 2008 Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors ANZ J Surg 78 42 48 18199204 10.1111/j.1445-2197.2007.04354.x
30. P Meijnen HS Oldenburg JL Peterse H Bartelink EJ Rutgers 2008 Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast Ann Surg Oncol 15 235 243 17987342 10.1245/s10434-007-9659-2
31. GP Boland KC Chan WF Knox SA Roberts NJ Bundred 2003 Value of the Van Nuys prognostic index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery Br J Surg 90 426 432 12673743 10.1002/bjs.4051 1:STN:280:DC%2BD3s7ls1yitw%3D%3D (Pubitemid 36458104)
32. NL Barnes S Khavari GP Boland A Cramer WF Knox NJ Bundred 2005 Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast Clin Cancer Res 11 2163 2168 15788662 10.1158/1078-0432.CCR-04-1633 1:CAS:528:DC%2BD2MXisFajtbc%3D (Pubitemid 40490173)
33. S Altintas K Lambein MT Huizing, et al. 2009 Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study Breast J 15 120 132 19292797 10.1111/j.1524-4741.2009.00686.x 1:CAS:528:DC%2BD1MXksFehtLo%3D
34. Schouten van der Velden AP, van Vugt R, Van Dijck JA, Leer JW, Wobbes T (2007) Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: a population-based study in the East Netherlands. Int J Radiat Oncol Biol Phys 69:703-710 (Pubitemid 47418402)
35. A Omlin M Amichetti D Azria, et al. 2006 Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network Lancet Oncol 7 652 656 16887482 10.1016/S1470-2045(06)70765- 3 (Pubitemid 44143777)
36. HR MacDonald MJ Silverstein H Mabry, et al. 2005 Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Am J Surg 190 521 525 16164913 10.1016/j.amjsurg.2005.06.005 (Pubitemid 41306068)
37. DB Cornfield JP Palazzo GF Schwartz, et al. 2004 The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone Cancer 100 2317 2327 15160334 10.1002/cncr.20260 (Pubitemid 38657878)
38. S Stallard DA Hole AD Purushotham, et al. 2001 Ductal carcinoma in situ of the breast-among factors predicting for recurrence, distance from the nipple is important Eur J Surg Oncol 27 373 377 11417983 10.1053/ejso.2001.1123 1:STN:280:DC%2BD3MzlslGrsg%3D%3D (Pubitemid 32624539)
39. S Sahoo WM Recant N Jaskowiak L Tong R Heimann 2005 Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience Breast J 11 242 247 15982389 10.1111/j.1075-122X.2005.21617.x (Pubitemid 41026037)
40. MA de Roos GH de Bock J de Vries B van der Vegt J Wesseling 2007 p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast J Surg Res 140 109 114 17291532 10.1016/j.jss.2006.10.045 (Pubitemid 46669545)
41. E Rakovitch JP Pignol W Hanna, et al. 2007 Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy J Clin Oncol 25 35 5591 5596 17984188 10.1200/JCO.2007.11.4686
42. AG Douglas-Jones J Logan JM Morgan R Johnson R Williams 2002 Effect of margins of excision on recurrence after local excision of ductal carcinoma in situ of the breast J Clin Pathol 55 581 586 12147650 10.1136/jcp.55.8.581 1:STN:280:DC%2BD38zpvVCmtw%3D%3D
43. E Provenzano JL Hopper GG Giles G Marr DJ Venter JE Armes 2003 Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast Eur J Cancer 39 622 630 12628841 10.1016/S0959-8049(02)00666-4 1:CAS:528:DC%2BD3sXhvFGkurs%3D (Pubitemid 36287374)
44. LA Habel JR Daling PA Newcomb, et al. 1998 Risk of recurrence after ductal carcinoma in situ of the breast Cancer Epidemiol Biomarkers Prev 7 689 696 9718221 1:STN:280:DyaK1czot1entQ%3D%3D (Pubitemid 28374599)
45. K Kerlikowske A Molinaro I Cha, et al. 2003 Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy J Natl Cancer Inst 95 1692 1702 14625260 (Pubitemid 37509078)
46. K Kerlikowske AM Molinaro ML Gauthier, et al. 2010 Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis J Natl Cancer Inst 5 102 627 637
47. JL Warren DL Weaver T Bocklage, et al. 2005 The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis Cancer 104 1840 1848 16136599 10.1002/cncr.21406 (Pubitemid 41513166)
48. CI Li KE Malone BS Saltzman JR Daling 2006 Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001 Cancer 106 2104 2112 16604564 10.1002/cncr.21864 (Pubitemid 43673230)
49. BD Smith BG Haffty TA Buchholz, et al. 2006 Effectiveness of radiation therapy in older women with ductal carcinoma in situ J Natl Cancer Inst 98 1302 1310 16985249 10.1093/jnci/djj359 (Pubitemid 44538160)
50. K Innos PL Horn-Ross 2008 Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast Breast Cancer Res Treat 111 531 540 17978879 10.1007/s10549-007-9807-1
51. F Warnberg J Bergh M Zack L Holmberg 2001 Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden Cancer Epidemiol Biomarkers Prev 10 495 499 11352860 1:STN:280:DC%2BD3M3lsVKjuw%3D%3D (Pubitemid 32701636)
52. LJ Solin A Fourquet FA Vicini, et al. 2005 Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast Cancer 103 1137 1146 15674853 10.1002/cncr.20886 (Pubitemid 40328083)
53. GW Carlson A Page E Johnson K Nicholson TM Styblo WC Wood 2007 Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy J Am Coll Surg 204 1074 1078 17481544 10.1016/j.jamcollsurg.2007.01.063 (Pubitemid 46661213)
54. I de Mascarel G MacGrogan S Mathoulin-Pélissier I Soubeyran V Picot JM Coindre 2002 Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas Cancer 94 2134 2142 12001109 10.1002/cncr.10451 (Pubitemid 34411969)
55. S Di Saverio F Catena D Santini, et al. 2008 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up Breast Cancer Res Treat 109 405 416 17687650 10.1007/s10549-007-9668-7 (Pubitemid 351692055)
56. NA Miller JA Chapman EB Fish, et al. 2001 In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma Breast J 7 292 302 11906438 10.1046/j.1524-4741.2001.99124.x 1:STN:280:DC%2BD387nt1Crsg%3D%3D (Pubitemid 33101633)
57. FA Vicini LL Kestin NS Goldstein, et al. 2000 Impact of young age on outcome in patients with ductal carcinoma-in situ treated with breast-conserving therapy J Clin Oncol 18 296 306 10637243 1:STN:280:DC%2BD3c7gsFektg%3D%3D (Pubitemid 30056418)
58. C Vargas L Kestin N Go, et al. 2005 Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy Int J Radiat Oncol Biol Phys 63 1514 1521 16005576 10.1016/j.ijrobp.2005.04.045 (Pubitemid 41628051)
59. MJ Siverstein MD Lagios S Groshen, et al. 1999 The influence of margin width on local control of ductal carcinoma in situ of the breast N Engl J Med 340 1455 1461 10.1056/NEJM199905133401902 (Pubitemid 29220544)
60. NS Goldstein L Kestin F Vicini 2000 Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy Am J Surg Pathol 24 1058 1067 10935646 10.1097/00000478-200008000-00003 1:STN:280:DC%2BD3czpvFKqtQ%3D%3D (Pubitemid 30612827)
61. M Azu P Abrahamse SJ Katz R Jagsi M Morrow 2010 What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates Ann Surg Oncol 17 558 563 19847566 10.1245/s10434-009-0765-1
62. SL Blair K Thompson J Rococco V Malcarne PD Beitsch DW Ollila 2009 Attaining negative margins in breast-conservation operations: is there a consensus among breast surgeons? J Am Coll Surg 209 608 613 19854401 10.1016/j.jamcollsurg.2009.07.026
63. C Dunne JP Burke M Morrow MR Keller 2009 Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ J Clin Oncol 27 1615 1620 19255332 10.1200/JCO.2008.17.5182
64. J Houghton WD George J Cuzick, et al. 2003 Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial Lancet 362 95 103 12867108 10.1016/S0140-6736(03)13859-7 (Pubitemid 36831018)
65. Allred D, Bryant J, Land S et al (2002) Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 76:S36 (suppl 1; abstr 30)
66. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer-V.2.2011. National Comprehensive Cancer Network Inc, Fort Washington. Available at: http://www.nccn.org/professionals/physiciangls/PDF/breast.pdf. Accessed December 31, 2010
67. L Harris H Fritsche R Mennel, et al. 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 17954709 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK (Pubitemid 350232263)
68. SC Lester S Bose YY Chen, et al. 2009 Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast Arch Pathol Lab Med 133 15 25 19123730
69. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
70. J Zhang KF Yu 1998 What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes JAMA 280 1690 1691 9832001 10.1001/jama.280.19.1690 1:STN:280:DyaK1M%2FkvVynsw%3D%3D (Pubitemid 28532993)